Rituximab mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis

Background: Rituximab (RTX), a CD20 depleting agent, is a frequently used off-label treatment for multiple sclerosis (MS), while mitoxantrone (MTX) is approved, albeit rarely used for active relapsing MS (RMS). However, observational data comparing RTX and MTX effectiveness and safety are scarce. Ob...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Tobias Zrzavy, Esther Daniels, Niklas Stuka, Dennis Weber, Alexander Winkelmann, Helmut Rauschka, Michael Hecker, Fahmy Aboulenein-Djamshidian, Stefanie Meister, Fritz Leutmezer, Thomas Berger, Gabriel Bsteh, Uwe Klaus Zettl, Paulus Rommer
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	SAGE Publishing 2021-07-01
Schriftenreihe:	Therapeutic Advances in Chronic Disease
Online-Zugang:	https://doi.org/10.1177/20406223211024366
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!